Merck & Co.MRK

About Merck & Co.

Merck & Co., Inc. is a global pharmaceutical company that develops, manufactures, and markets prescription medicines and vaccines for human use, alongside a smaller animal health business serving livestock and companion animals. Its human health portfolio spans oncology, vaccines, hospital acute care, immunology, cardiovascular, virology, and diabetes, with the oncology franchise anchored by the PD-1 checkpoint inhibitor Keytruda, which has become the largest single source of revenue and profit for the company. Vaccines including Gardasil for HPV and the pediatric and pneumococcal franchises contribute meaningfully, while the animal health unit provides a diversifying stream. The pharmaceutical segment overwhelmingly drives operating profit, with Keytruda alone representing a disproportionate share.

Investors track a concentrated set of structural issues. The dominance of Keytruda creates significant exposure to the loss-of-exclusivity cliff expected in the second half of this decade, making pipeline replacement, subcutaneous reformulation strategy, and lifecycle patent management central concerns. Regulatory scrutiny under the U.S. Inflation Reduction Act's Medicare drug price negotiation program is a durable overhang, as are pediatric vaccine access decisions and international reference pricing. Merck is a component of major U.S. large-cap indices and the Dow Jones Industrial Average. Capital allocation blends a long-standing dividend, share repurchases, and bolt-on business development, and governance features include a unified board structure with an independent chair role that has varied over time.

Merck traces its U.S. origins to 1891 as the American subsidiary of the German chemical house E. Merck, becoming an independent American company after being seized during the First World War. It grew into a research-driven pharmaceutical leader through the twentieth century, notably merging with Sharp & Dohme in 1953. The modern corporation was shaped by the 2009 acquisition of Schering-Plough, which added biologics capacity, the Nasonex and Remicade franchises, and the animal health operations later merged into Merck Animal Health. In 2021 the company spun off its women's health, legacy brands, and biosimilars businesses as Organon & Co., sharpening the parent's focus on novel oncology, vaccines, and hospital specialty therapeutics.

Merck sells prescription medicines primarily to wholesalers and distributors such as the large U.S. drug channel intermediaries, which resell to pharmacies, hospitals, clinics, and government purchasers, while vaccines flow substantially through public health programs and physician offices. Net pricing is shaped by rebates negotiated with pharmacy benefit managers, managed care organizations, and, increasingly, government negotiators, meaning gross-to-net adjustments are material. Competitive position rests on patent-protected innovation, clinical trial breadth, manufacturing scale for complex biologics and vaccines, and a global commercial footprint competing with Pfizer, Bristol Myers Squibb, Roche, Novartis, AstraZeneca, and Johnson & Johnson. International markets contribute a substantial share of revenue, with the United States remaining the largest single geography.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full SEC-based report on Merck & Co. →